Literature DB >> 11427198

The apoAI-CIII-AIV gene cluster.

M Groenendijk1, R M Cantor, T W de Bruin, G M Dallinga-Thie.   

Abstract

The relationship between variations in the apoAI-CIII-AIV gene cluster and plasma lipid traits has been recognized for at least 15 years. Most studies have been focused upon the association between plasma triglycerides and a genetic variation present in the 3' untranslated region of the apoC-III gene (SstI polymorphism). Although not all studies showed similar results, this variant is most consistently found in association with plasma triglycerides. The other most interesting DNA variant is the mutation present in the promoter region of the apo A-I gene at position -75 (Msp-AI polymorphism), which has been associated with differences in plasma apoA-I and HDL-cholesterol levels. In this review, we will discuss the most frequent occurring genetic variants in the apoAI-CIII-AIV gene cluster and their impact on plasma lipid traits and associations with increased risk on developing coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427198     DOI: 10.1016/s0021-9150(01)00539-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

1.  The apolipoprotein CIII T2854G variants are associated with postprandial triacylglycerol concentrations in normolipidemic Korean men.

Authors:  Sang-Koo Woo; Hyun-Sik Kang
Journal:  J Hum Genet       Date:  2003-09-27       Impact factor: 3.172

2.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

3.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

4.  The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability.

Authors:  C M Brown; T J Rea; S C Hamon; J E Hixson; E Boerwinkle; A G Clark; C F Sing
Journal:  J Mol Med (Berl)       Date:  2006-05-17       Impact factor: 4.599

5.  Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm.

Authors:  Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

6.  Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11.

Authors:  Michael Olivier; Xujing Wang; Regina Cole; Brian Gau; Jessica Kim; Edward M Rubin; Len A Pennacchio
Journal:  Genomics       Date:  2004-05       Impact factor: 5.736

7.  An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese.

Authors:  Keisuke Shioji; Toshifumi Mannami; Yoshihiro Kokubo; Yoichi Goto; Hiroshi Nonogi; Naoharu Iwai
Journal:  J Hum Genet       Date:  2004-07-17       Impact factor: 3.172

8.  Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.

Authors:  Yongjun Liu; Jose M Ordovas; Guimin Gao; Michael Province; Robert J Straka; Michael Y Tsai; Chao-Qiang Lai; Kui Zhang; Ingrid Borecki; James E Hixson; David B Allison; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2009-02       Impact factor: 2.089

9.  Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke.

Authors:  Anita Maász; Péter Kisfali; Zoltán Szolnoki; Ferenc Hadarits; Béla Melegh
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

10.  Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome.

Authors:  Anita Maász; Péter Kisfali; Katalin Horvatovich; Márton Mohás; Lajos Markó; Veronika Csöngei; Bernadett Faragó; Luca Járomi; Lili Magyari; Enikô Sáfrány; Csilla Sipeky; István Wittmann; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.